This study was novel in demonstrating that CGA, previously regarded as a chemopreventive drug in several types of cancer, might confer radioresistance in HCC through modulating the ROS/Nrf2 signaling pathway. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.